title: Determination of a novel phosphodiesterase4 inhibitor, 3-[1-(3cyclopropylmethoxy-4-difluoromethoxybenzyl)-1H-pyrazol-3-yl]-benzoic acid (PDE-423) in rat plasma using liquid chromatography-tandem mass spectrometry.
abstract: A method for determining a novel phosphodiesterase-4 inhibitor, 3-[1-(3cyclopropylmethoxy-4-difluoromethoxybenzyl)-1H-pyrazol-3-yl]-benzoic acid (PDE-423), in rat plasma was developed and validated using liquid chromatography-tandem mass spectrometry for further pharmacokinetic study for development as a novel anti-asthmatic drug. PDE-423 in the concentration range of 0.02-10 µg/mL was linear with a correlation coefficient of >0.99, and the mean intra- and inter-assay precisions of the assay were 7.50 and 3.86%, respectively. The validated method was used successfully for a pharmacokinetic study of PDE-423 in rats.
authors: Drug Discovery Platform Technology Group, Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea; College of Pharmacy, ChungNam National University, Daejeon, Republic of Korea.
authors: Woon-Ki
authors: WK
authors: Cho
authors: Hyewon
authors: H
authors: Seo
authors: Sung Heum
authors: SH
authors: Choi
authors: Hyun Jeong
authors: HJ
authors: Kwak
authors: Hyae Gyeong
authors: HG
authors: Cheon
authors: Dong Ju
authors: DJ
authors: Jeon
authors: Sang Kyum
authors: SK
authors: Kim
authors: Myung Ae
authors: MA
authors: Bae
authors: Jin Sook
authors: JS
authors: Song
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001565:Benzoates / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics*; D001682:Biological Availability; D002853:Chromatography, Liquid / Q000379:methods*; D059625:Liquid-Liquid Extraction; D008297:Male; D058988:Phosphodiesterase 4 Inhibitors / Q000097:blood* / Q000493:pharmacokinetics; D011720:Pyrazoles / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics*; D017207:Rats, Sprague-Dawley; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D053719:Tandem Mass Spectrometry / Q000379:methods*
chemical_list: C575161:3-(1-(3-cyclopropylmethoxy-4-difluoromethoxybenzyl)-1H-pyrazol-3-yl)benzoic acid; D001565:Benzoates; D058988:Phosphodiesterase 4 Inhibitors; D011720:Pyrazoles
keywords: LC-MS/MS; PDE-423; method validation; pharmacokinetics; rat plasma